European shares end marginally lower on tech drag; Fed in focus
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
France's Rexel jumps after rejecting $9.4 bln QXO bid
UK insurer Phoenix falls on halting sale of unit SunLife
STOXX 600 down 0.2%
Updated at 1600 GMT
By Shubham Batra and Shashwat Chauhan
Sept 16 (Reuters) -Europe's STOXX 600 closed slightly lower on Monday as losses in heavyweight technology shares weighed on the index, while the focus remained on the U.S. Federal Reserve, which is widely expected to kick off its policy easing cycle this week.
The pan-European STOXX 600 index .STOXX ended 0.2% lower, snapping a three-day winning streak.
Europe's tech index .SX8P dipped 1.2%, the biggest percentage decliner amongst major STOXX sectors, following its near 5% jump last week.
Retail .SXRP led advances with an 0.9% rise, boosted by a 3.1% increase in H&M HMb.ST.
All eyes will be on the U.S. central bank's interest rate decision on Wednesday, with money markets pencilling in a 61% chance of a 50-basis-point rate cut, and a total easing of 120 bps in 2024.
"With the Fed set to hop aboard the (rate-cut) bandwagon, a global easing cycle should be a tailwind for equities after the European Central Bank opted to cut rates for the second time in three months," wrote analysts at Glenmede led by Jason Pride, chief of investment strategy & research.
"Momentum behind global easing cycles has historically been a bullish signal for equities in the short-to-medium term."
Central bank rate decisions in Norway and the UK will also be on investors' radar this week.
The ECB's chief economist Philip Lane said the bank should keep cutting interest rates gradually, but its policymakers expressed differing views on how to signal their intent given economic uncertainty.
Among individual movers, France's Rexel RXL.PA jumped 9.1% after the Paris-listed group rebuffed an around $9.4 billion acquisition offer from billionaire Brad Jacobs-led QXO QXO.O.
French drugmaker Ipsen IPN.PA rose 3.7% after RBC raised its rating to "outperform" from "sector perform", seeing mid-term support from its liver disease drug Iqirvo (PBC) after its U.S. FDA approval in June.
On the flip side, shares of Nestle NESN.S weighed on the benchmark index with a 1% fall after Morgan Stanley cut the stock's rating to "underweight" and reduced its target price.
France's Worldline WLN.PA slumped 15.2%, extending losses from Friday when the payments group said its long-time CEO Gilles Grapinet would leave the company as it issued its third profit warning.
Phoenix Group PHNX.L shed 5.3% after the British insurer halted the sale process of its SunLife business due to market uncertainty.
Reporting by Shubham Batra and Shashwat Chauhan in Bengaluru; Editing by Sherry Jacob-Phillips, Abinaya Vijayaraghavan and Jonathan Oatis
Aset Terkait
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
